DiscoveryProbe™ FDA-approved Drug Library: High-Content Screening & Drug Repositioning Resource

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 clinically approved compounds covering a broad spectrum of mechanisms of action, including receptor agonists, antagonists, and enzyme inhibitors (product page). The library's compounds are sourced from major regulatory approvals (FDA, EMA, HMA, CFDA, PMDA) or recognized pharmacopeias, ensuring high translational relevance. Provided as pre-dissolved 10 mM DMSO solutions, the collection is compatible with high-throughput (HTS) and high-content screening (HCS) workflows, facilitating rapid drug repositioning and target identification (Labpe 2023). Benchmarking studies demonstrate its effectiveness in G protein-coupled receptor (GPCR) ligand discovery, with 9% of ~1,800 drugs tested activating TAS2R14 bitter taste receptors (Fierro et al., 2023). The library is stable for up to 24 months at -80°C, and ships in flexible formats for diverse assay systems.

Biological Rationale

Screening clinically approved drug libraries enables systematic identification of new pharmacological activities, supporting drug repositioning and target deconvolution. G protein-coupled receptors (GPCRs) represent one of the largest families of drug targets, with over 450 FDA-approved drugs acting on GPCRs—comprising approximately one-third of all FDA-approved medicines (Fierro et al., 2023). Bitter taste receptors (TAS2Rs), a subfamily of GPCRs, are expressed in both oral and extra-oral tissues and implicated in diverse physiological and pathological processes. Drug libraries such as DiscoveryProbe™ facilitate systematic, high-throughput exploration of complex target spaces and are instrumental for translational research in fields such as oncology, neurodegeneration, and immunology (GSKChem 2023—this article expands on mechanistic coverage compared to GSKChem's focus on workflow optimization).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library contains compounds with well-characterized mechanisms, including:

• Receptor agonists and antagonists (e.g., GPCR modulators such as β-blockers and antihistamines).
• Enzyme inhibitors (e.g., kinase inhibitors, protease inhibitors).
• Ion channel modulators (e.g., calcium and potassium channel blockers).
• Signal pathway regulators (e.g., PI3K/AKT/mTOR inhibitors).

Representative compounds include doxorubicin (topoisomerase II inhibitor), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor). Each compound's inclusion is based on regulatory approval and characterization in standard pharmacopeias, ensuring relevance for translational and mechanistic studies (DiscoveryProbe™ FDA-approved Drug Library).

Evidence & Benchmarks

• The DiscoveryProbe™ library enabled the identification of 10 new TAS2R14 antagonists and 200 new agonists via iterative experimental screening and virtual modeling (Fierro et al., 2023, https://doi.org/10.1007/s00018-023-04765-0).
• 9% of ~1,800 pharmaceutical drugs tested from FDA-approved libraries activated the TAS2R14 receptor, with nine compounds demonstrating sub-micromolar activation potency (Fierro et al., 2023, https://doi.org/10.1007/s00018-023-04765-0).
• GPCR-targeting drugs constitute ~33% of all FDA-approved drugs, with 52% functioning as antagonists (Fierro et al., 2023, https://doi.org/10.1007/s00018-023-04765-0).
• The library's pre-dissolved, 10 mM DMSO solutions are compatible with most HTS/HCS platforms, and compounds remain stable for 12 months at -20°C or 24 months at -80°C (product documentation).
• Validated for use in cancer and neurodegenerative disease models, supporting both target-based and phenotypic screening workflows (Labpe 2023—this article details mechanistic diversity not covered in Labpe's application focus).

Applications, Limits & Misconceptions

• Drug Repositioning Screening: Enables rapid identification of novel indications for existing drugs by repurposing clinically approved molecules (A-Amanitin 2023—this article extends mechanistic detail beyond A-Amanitin's workflow focus).
• Pharmacological Target Identification: Supports deconvolution of phenotypic screens to uncover molecular targets or off-target effects of approved drugs.
• Cancer Research Drug Screening: Facilitates HTS/HCS for cytotoxicity, proliferation, and pathway modulation in oncology models.
• Neurodegenerative Disease Drug Discovery: Used to identify compounds modulating neuroprotective, anti-inflammatory, or synaptic pathways.
• Signal Pathway Regulation Studies: Empowers researchers to dissect complex signaling networks via well-annotated pharmacological probes.

Common Pitfalls or Misconceptions

• The library is not exhaustive for all chemical or mechanistic classes; it is limited to regulatory-approved or pharmacopeia-listed compounds.
• Activity observed in screening may not translate to efficacy in vivo due to differences in pharmacokinetics or tissue distribution.
• Compounds are pre-dissolved in DMSO; some cell types or assays may require further dilution to avoid solvent toxicity.
• Not all compounds are suitable for all biological assay formats; solubility or stability must be confirmed for non-standard conditions.
• The collection is not intended for direct clinical administration—research use only.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is provided as 10 mM solutions in DMSO, aliquoted in 96-well or deep well plates, or 2D barcoded screw-top tubes. This format is compatible with automated liquid handling, minimizing pipetting errors and cross-contamination. The stability of the compounds is validated for 12 months at -20°C and 24 months at -80°C. The library can be shipped on blue ice for evaluation samples and at room temperature or blue ice for larger orders.

Typical workflows include:

• Assay miniaturization for high-throughput screening (HTS), with volumes as low as 2–10 μL per well.
• High-content imaging systems for multiparametric phenotypic assays.
• Integration with target deconvolution methodologies, including chemoproteomics and transcriptomics.

Data analysis pipelines can leverage well-documented compound annotations, including regulatory status, mechanism of action, and chemical structure. This supports streamlined hit triage and mechanistic follow-up (Agar-Bacteriological 2023—this article details advanced integration options beyond Agar-Bacteriological's overview).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a validated, high-content resource for drug discovery, target identification, and translational research. Its clinically relevant, well-characterized compound set accelerates drug repositioning and mechanistic studies in diverse disease models. Benchmarking studies confirm its utility for identifying novel modulators of complex targets, such as TAS2R14, and for systematic screening of pharmacological space (Fierro et al., 2023). Ongoing expansion of compound annotations and integration with next-generation screening platforms will further enhance its value for life sciences research.

For detailed specifications and ordering, visit the DiscoveryProbe™ FDA-approved Drug Library product page.